INTRAVENOUS GAMMA-GLOBULIN AS ADJUNCT THERAPY FOR SEVERE GROUP-B STREPTOCOCCAL DISEASE IN THE NEWBORN

被引：25

作者：

FRIEDMAN, CA

WENDER, DF

TEMPLE, DM

RAWSON, JE

机构：

[1] Hinds General Hospital and Mississippi Baptist Medical Center, Jackson, Mississippi

来源：

AMERICAN JOURNAL OF PERINATOLOGY | 1990年 / 7卷 / 01期

关键词：

D O I：

10.1055/s-2007-999433

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Group B streptococcal (GBS) disease remains a significant cause of morbidity and mortality among newborns despite aggressive antibiotic and supportive therapy. Recent success with the prophylactic use of intravenous gamma globulin (IVIg) in newborns suggests that use of IVIg may be an additional therapy for infants with severe GBS disease. Eighty-four infants with GBS antigen in serum, urine, and in some cases spinal fluid were identified by a rapid latex agglutination assay. Twenty-four of these infants had both neutropenia and serum GBS antigen titers of 1:10 or greater and had the highest risk of dying from their infection. Before the availability of IVIg, seven of the first 12 of these infants identified with the highest risk factors died (58%). Twelve additional patients with these highest risk factors have been treated with IVIg. Two of these 12 died (17%), p < 0.01 when compared with the previous highest risk group. In surviving patients in both IVIg-treated and non-IVIg-treated groups, the time for recovery from neutropenia was 2 to 4 days. Our study suggests a possible beneficial effect of IVIg as adjunct therapy in severe GBS disease. © 1990, by Thieme Medical Publishers, Inc. All rights reserved.

引用

页码：1 / 4

页数：4

共 15 条

[1]

Dillon H.C., Khare S., Gray B.M., Group B streptococcal carriage and disease: A six year prospective study, J Pediatr, 110, pp. 31-36, (1987)

[2]

Baker C.J., Edwards M.S., Kasper D.L., Role of antibody to native type III polysaccharide of group B streptococcus in infant infection, Pediatrics, 68, pp. 544-549, (1981)

[3]

Sidiropoulos D., Morell A., Nydegger U.E., Clinical Use of Intravenous Immunoglobulins, pp. 159-170, (1986)

[4]

Chirico G., Rondini G., Plebani A., Chiara A., Massa M., Ugazio A.G., Intravenous gammaglobulin therapy for prophylaxis of infection in high-risk neonates, J Pediatr, 110, pp. 437-442, (1987)

[5]

Stiehm E.F., Intravenous immunoglobulins as therapeutic agents, Ann Intern Med, 107, pp. 367-382, (1987)

[6]

Friedman C.A., Wender D.F., Rawson J.E., Rapid diagnosis of Group B streptococcal infection utilizing a commercially available latex agglutination assay, Pediatrics, 73, pp. 27-30, (1984)

[7]

McCracken G.H., Nelson J.D., In Antimicrobial Therapy for Newborns, New York: Grune & Stratton, pp. 119-127, (1983)

[8]

Christensen K.K., Christensen P., Bucher H.U., Due G., Kind C.H., Mieth D., Muller B., Seger R.A., Intravenous administration of human IgG to newborn infants: Changes in serum antibody levels to group B streptococci, Eur J Pediatr, 143, pp. 123-127, (1984)

[9]

Haque K.N., Zaide M.H., Haque S.K., Bahakim H., El-Hazmi M., El-Swailam M., Intravenous immunoglobulin for prevention of sepsis in preterm and low birth weight infants, Pediatr Infect Dis, 5, pp. 622-625, (1986)

[10]

McFall T.L., Zimmerman G.A., Augustine N.H., Hill H.R., Effect of group B streptococcal type-specific antigen on polymorphonuclear leukocyte function and polymorphonuclear leukocyte-endothelial cell interaction, Pediatr Res, 21, pp. 517-523, (1987)

← 1 2 →